Ken Griffin Kazia Therapeutics LTD Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kazia Therapeutics LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 78,800 shares of KZIA stock, worth $245,068. This represents 0.0% of its overall portfolio holdings.
Number of Shares
78,800
Previous 24,000
228.33%
Holding current value
$245,068
Previous $5,000
560.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding KZIA
# of Institutions
21Shares Held
2.13MCall Options Held
93.2KPut Options Held
0-
Mai Capital Management1.36MShares$4.24 Million0.01% of portfolio
-
Ubs Group Ag249KShares$775,7950.0% of portfolio
-
Morgan Stanley New York, NY220KShares$685,0110.0% of portfolio
-
Jane Street Group, LLC New York, NY46.1KShares$143,4020.0% of portfolio
-
United Bank Vienna, VA44KShares$136,8400.0% of portfolio
About KAZIA THERAPEUTICS LTD
- Ticker KZIA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,111,300
- Market Cap $47M
- Description
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...